4D Molecular Therapeutics vs Regenxbio
FDMT and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FDMT and RGNX compare
4D Molecular Therapeutics is the larger company, worth 1.7 times as much as Regenxbio ($938M against $559M).
4D Molecular Therapeutics grew revenue faster over the last twelve months (278712% versus 12.0% for Regenxbio).
Regenxbio keeps more of each dollar of sales as profit, with a net margin of −113% compared with −195% at 4D Molecular Therapeutics.
4D Molecular Therapeutics scores higher on the StockData Score (7 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FDMT | RGNX |
|---|---|---|
| Size and price | ||
| Market cap | $938M | $559M |
| Share price | $12.99 | $8.47 |
| Change, 1 year | 27.7% | −23.1% |
| Change, 5 years | −43.7% | −74.7% |
| Beta (5Y) | 1.35 | 1.79 |
| Employees | 196 | 371 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.2× | 3.2× (better) |
| P/B | 2.3× (better) | 7.8× |
| FCF yield | – | −44.7% |
| Fair value | $12.76 | – |
| Margin of safety | −1.8% | – |
| Growth | ||
| Revenue growth (TTM) | 278712% (better) | 12.0% |
| Revenue growth, 5Y average | 44.3% (better) | 2.0% |
| Profitability | ||
| Operating margin | −214% | −94.1% (better) |
| Net margin | −195% | −113% (better) |
| FCF margin | – | −143% |
| Return on equity | −43.3% (better) | −138% |
| Return on invested capital | −161% | – |
| Financial health | ||
| Debt / equity | 0.05 | – |
| Interest coverage | – | −3.9× |
| Current ratio | 8.03 (better) | 2.86 |
| Altman Z-score | 3.87 (better) | −3.73 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 80.5% | 64.2% |
| Held by insiders | 2.1% | 7.6% |
| Insider net buying, 12 months | −$5.3M | $9.6K (better) |
| Short interest, % of float | 15.4% | 16.7% |
Go deeper
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
- RGNX stock overview
- RGNX income statement
- RGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.